CX-2051

CytomX Therapeutics has dosed the first patient in a Phase 1 trial combining its masked interferon alpha-2b (CX-801) with Merck's Keytruda in patients with metastatic melanoma.

CytomX's EpCAM-targeting antibody-drug conjugate CX-2051 demonstrated a 28% confirmed response rate in late-line colorectal cancer patients, significantly outperforming current standard therapies with single-digit response rates.

CytomX Therapeutics, a clinical-stage biopharmaceutical company, is at a critical juncture with its innovative cancer treatments. With a focus on solid tumors, the company is advancing its clinical pipeline, including the lead candidate EGFRxCD3 (CX-904) for advanced solid tumors and EpCAM ADC (CX-2051) for colorectal cancer. Despite financial challenges and a recent workforce reduction, CytomX has extended its cash runway and maintains strategic partnerships, notably with Amgen, to bolster its position in the competitive oncology market.

Biopharma companies continue to announce layoffs in 2025, driven by strategic realignments, pipeline reprioritizations, and challenging financial conditions.

Cytokinetics anticipates a pivotal year in 2025, focusing on the potential FDA approval and commercial launch of aficamten for obstructive hypertrophic cardiomyopathy (HCM) in the U.S.